The multiple facets of drug resistance: One history, different approaches

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Niero, Evandro Luís ^a   Rocha Sales, Bianca ^a   Lauand, Camila ^a   Cortez, Beatriz Araujo ^a   De Souza, Marcelo Medina ^a   Rezende Teixeira, Paula ^a   Urabayashi, Marcel Shiniti ^a   Martens, Adam Arai ^a   Neves, Jorge Henrique ^a   Machado Santelli, Gláucia Maria ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

3D cell culture; Cancer stem cells; Cell death; Chemoresistance; Multidrug resistance

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ABC TRANSPORTER; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CYCLIN D1; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; MONOCLONAL ANTIBODY MRK 16; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; TAMOXIFEN;

ACTIVE TRANSPORT; BREAST CANCER CELL LINE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STEM CELL; CARCINOGENESIS; CELL ADHESION; CELL DEATH; DNA DAMAGE; DRUG RESISTANCE; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; HUMAN; INTRACELLULAR SIGNALING; LONG TERM CARE; MULTIDRUG RESISTANCE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT; TUMOR RESISTANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HEAT-SHOCK PROTEINS; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; NEOPLASTIC STEM CELLS; TUMOR CELLS, CULTURED;

EID: 84902008991     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-33-37     Document Type: Review

References (167)

1. The birth of chemotherapy at Yale. Bicentennial lecture series: Surgery Grand Round. Christakis P, Yale J Biol Med 2011 84 169 172 21698052
2. A tribute to Sidney Farber- the father of modern chemotherapy. Miller DR, Br J Haematol 2006 134 20 26 10.1111/j.1365-2141.2006.06119.x 16803563 (Pubitemid 43830023)
3. Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-mercaptopurine and methotrexate. Frei E, Freireich E, Gehan E, Blood 1961 18 431 454
4. The effect of 6-mercaptopurine on the duration of steroid-induced remissions in acute leukemia: a model for evaluation of other potentially useful therapy. Freireich E, Gehan E, Blood 1963 21 699 716
5. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Frei E, Karon M, Levin RH, Freireich EJ, Taylor RJ, Hananian J, Selawry O, Holland JF, Hoogstraten B, Wolman IJ, Abir E, Sawitsky A, Lee S, Mills SD, Burgert EO, Spurr CL, Patterson RB, Ebaugh FG, James GW, Moon JH, Blood 1965 26 642 656 5321112
6. A history of cancer chemotherapy. DeVita VT, Chu E, Cancer Res 2008 68 8643 8653 10.1158/0008-5472.CAN-07-6611 18974103
7. Origin of the resistance of leukaemic cells to folic acid antagonists. LAW LW, Nature 1952 169 628 629 10.1038/169628a0 14929259
8. Mutations of bacteria from virus sensitivity to virus resistance. Luria SE, Delbrück M, Genetics 1943 28 491 511 17247100
9. Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis. Chen Y, Liu H, Wu W, Li Y, Li J, J Exp Clin Cancer Res 2013 32 45 10.1186/1756-9966-32-45 23883434
10. TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer. Wang N, Zhang H, Yao Q, Wang Y, Dai S, Yang X, J Exp Clin Cancer Res 2012 31 6 10.1186/1756-9966-31-6 22248469
11. Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl. Wang G, Zhang J, Liu L, Sharma S, Dong Q, PLoS One 2012 7 51764 10.1371/journal.pone.0051764 23240061
12. Membrane transport of alkylating agents. Goldenberg GJ, Begleiter A, Pharmacol Ther 1980 8 237 274 10.1016/0163-7258(80)90048-0 6992155 (Pubitemid 10117999)
13. Membrane transport alterations as a mechanism of resistance to anticancer agents. Fry DW, Jackson RC, Cancer Surv 1986 5 47 79 3297313
14. Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response. Kessel D, Botterill V, Wodinsky I, Cancer Res 1968 28 938 941 5652307
15. The clonal evolution of tumor cell populations. Nowell PC, Science 1976 194 23 28 10.1126/science.959840 959840
16. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE, Nature 1994 367 645 648 10.1038/367645a0 7509044 (Pubitemid 24067706)
17. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Bonnet D, Dick JE, Nat Med 1997 3 730 737 10.1038/nm0797-730 9212098 (Pubitemid 27298715)
18. Cancer stem cells: current status and evolving complexities. Visvader JE, Lindeman GJ, Cell Stem Cell 2012 10 717 728 10.1016/j.stem.2012.05.007 22704512
19. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Bai J, Sui J, Demirjian A, Vollmer CM, Marasco W, Callery MP, Cancer Res 2005 65 2344 2352 10.1158/0008-5472.CAN-04-3502 15781649 (Pubitemid 40490145)
20. Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells. Wang W, Cassidy J, Br J Cancer 2003 88 624 629 10.1038/sj.bjc.6600753 12592379 (Pubitemid 36363374)
21. Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Wang W, McLeod HL, Cassidy J, Int J Cancer 2003 104 504 511 10.1002/ijc.10972 12584750 (Pubitemid 36323923)
22. MDR gene expression analysis of six drug-resistant ovarian cancer cell lines. Januchowski R, Wojtowicz K, Sujka-Kordowska P, Andrzejewska M, Zabel M, Biomed Res Int 2013 2013 241763 23484165
23. Drug retention, efflux, and resistance in tumor cells. Krishan A, Fitz CM, Andritsch I, Cytometry 1997 29 279 285 10.1002/(SICI)1097-0320(19971201)29: 4<279::AID-CYTO3>3.0.CO;2-5 9415409 (Pubitemid 28032093)
24. Drug-selected coexpression of human glucocerebrosidase and P-glycoprotein using a bicistronic vector. Aran JM, Gottesman MM, Pastan I, Proc Natl Acad Sci U S A 1994 91 3176 3180 10.1073/pnas.91.8.3176 7909160 (Pubitemid 24130198)
25. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. Munoz M, Henderson M, Haber M, Norris M, IUBMB Life 2007 59 752 757 10.1080/ 15216540701736285 18085475 (Pubitemid 351412076)
26. Polyamines and membrane transporters. Abdulhussein AA, Wallace HM, Amino Acids 2013 46 655 660 23851697
27. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC, Proc Natl Acad Sci U S A 1987 84 7735 7738 10.1073/pnas.84.21.7735 2444983
28. The stem cell factor antibody enhances the chemotherapeutic effect of adriamycin on chemoresistant breast cancer cells. Jelly ND, Hussain II, Eremin J, Eremin O, El-Sheemy M, Cancer Cell Int 2012 12 21 10.1186/1475-2867-12-21 22642642
29. Phorbol ester TPA modulates chemoresistance in the drug sensitive breast cancer cell line MCF-7 by inducing expression of drug efflux transporter ABCG2. Kalalinia F, Elahian F, Hassani M, Kasaeeian J, Behravan J, Asian Pac J Cancer Prev 2012 13 2979 2984 10.7314/APJCP.2012.13.6.2979 22938493
30. Knocking down low molecular weight protein tyrosine phosphatase (LMW-PTP) reverts chemoresistance through inactivation of Src and Bcr-Abl proteins. Ferreira PA, Ruela-de-Sousa RR, Queiroz KCS, Souza ACS, Milani R, Pilli RA, Peppelenbosch MP, den Hertog J, Ferreira CV, PLoS One 2012 7 44312 10.1371/journal.pone.0044312 22957062
31. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance. Van Oosterwijk JG, Herpers B, Meijer D, Briaire-de Bruijn IH, Cleton-Jansen AM, Gelderblom H, van de Water B, Bovée JVMG, Ann Oncol 2012 23 1617 1626 10.1093/annonc/mdr512 22112972
32. Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. Sui H, Fan Z-Z, Li Q, J Int Med Res 2012 40 426 435 10.1177/147323001204000204 22613403
33. P-glycoprotein and MRP1 expression in axillary lymph node metastases of breast cancer patients. Zöchbauer-Müller S, Filipits M, Rudas M, Brunner R, Krajnik G, Suchomel R, Schmid K, Pirker R, Anticancer Res 2001 21 119 124 11299725 (Pubitemid 32267633)
34. Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant. dit Faute MA, Laurent L, Ploton D, Poupon M-F, Jardillier J-C, Bobichon H, Clin Exp Metastasis 2002 19 161 168 10.1023/A:1014594825502 11964080 (Pubitemid 34264086)
35. The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells. Shi Y, Liu C, Liu X, Tang DG, Wang J, PLoS One 2014 9 90022 10.1371/journal.pone.0090022 24595209
36. ABCC4 is regulated by microRNA-124a and microRNA-506. Markova SM, Kroetz DL, Biochem Pharmacol 2014 87 515 522 10.1016/j.bcp.2013.10.017 24184504
37. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Jiao X, Zhao L, Ma M, Bai X, He M, Yan Y, Wang Y, Chen Q, Zhao X, Zhou M, Cui Z, Zheng Z, Wang E, Wei M, Breast Cancer Res Treat 2013 139 717 730 10.1007/s10549-013-2607- x 23780685
38. Cytochrome c in the apoptotic and antioxidant cascades. Skulachev VP, FEBS Lett 1998 423 275 280 10.1016/S0014-5793(98)00061-1 9515723 (Pubitemid 28129349)
39. cis-Diamminedichloroplatinum (II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis- diamminedichloroplatinum (II). Fichtinger-Schepman AM, van Oosterom AT, Lohman PH, Berends F, Cancer Res 1987 47 3000 3004 3552211 (Pubitemid 17113451)
40. cis-Diamminedichloroplatinum (II)-DNA adduct formation in renal, gonadal, and tumor tissues of male and female rats. Reed E, Litterst CL, Thill CC, Yuspa SH, Poirier MC, Cancer Res 1987 47 718 722 3802077 (Pubitemid 17027962)
41. Platinum resistance in breast and ovarian cancer cell lines. Eckstein N, J Exp Clin Cancer Res 2011 30 91 10.1186/1756-9966-30-91 21967738
42. Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. De Brabander M, Geuens G, Nuydens R, Willebrords R, De Mey J, Proc Natl Acad Sci U S A 1981 78 5608 5612 10.1073/pnas.78.9.5608 6117858 (Pubitemid 12245199)
43. Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telophase. Long BH, Fairchild CR, Cancer Res 1994 54 4355 4361 7913875 (Pubitemid 24273147)
44. Clinical implications of p53 mutations. Wallace-Brodeur RR, Lowe SW, Cell Mol Life Sci 1999 55 64 75 10.1007/s000180050270 10065152 (Pubitemid 29077855)
45. No longer a molecular black box-new clues to apoptosis and drug resistance in melanoma. Satyamoorthy K, Bogenrieder T, Herlyn M, Trends Mol Med 2001 7 191 194 10.1016/S1471-4914(01)02013-5 11325619 (Pubitemid 32822884)
46. NF-kappaB in cancer: from innocent bystander to major culprit. Karin M, Cao Y, Greten FR, Li Z-W, Nat Rev Cancer 2002 2 301 310 10.1038/nrc780 12001991 (Pubitemid 37328783)
47. Tepoxalin enhances the activity of an antioxidant, pyrrolidine dithiocarbamate, in attenuating tumor necrosis factor alpha-induced apoptosis in WEHI 164 cells. Lee DH, Macintyre JP, Taylor GR, Wang E, Plante RK, Tam SS, Pope BL, Lau CY, J Pharmacol Exp Ther 1999 289 1465 1471 10336540 (Pubitemid 29246678)
48. Activators and target genes of Rel/NF-kappaB transcription factors. Pahl HL, Oncogene 1999 18 6853 6866 10.1038/sj.onc.1203239 10602461
49. Inhibition of NF-kappa B augments sensitivity to 5-fluorouracil/folinic acid in colon cancer. Voboril R, Hochwald SN, Li J, Brank A, Weberova J, Wessels F, Moldawer LL, Camp ER, MacKay SLD, J Surg Res 2004 120 178 188 10.1016/j.jss.2003.11.023 15234211 (Pubitemid 38834184)
50. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. El-Rayes BF, Ali S, Ali IF, Philip PA, Abbruzzese J, Sarkar FH, Cancer Res 2006 66 10553 10559 10.1158/0008-5472.CAN-06-2333 17079479 (Pubitemid 44799778)
51. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Arlt A, Gehrz A, Müerköster S, Vorndamm J, Kruse M, Fölsch UR, Schäfer H, Oncogene 2003 22 3243 3251 10.1038/sj.onc.1206390 12761494 (Pubitemid 36712936)
52. 3,3′-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Banerjee S, Wang Z, Kong D, Sarkar FH, Cancer Res 2009 69 5592 5600 10.1158/0008-5472.CAN-09-0838 19531648
53. Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Müerköster S, Arlt A, Witt M, Gehrz A, Haye S, March C, Grohmann F, Wegehenkel K, Kalthoff H, Fölsch UR, Schäfer H, Int J Cancer 2003 104 469 476 10.1002/ijc.10963 12584745 (Pubitemid 36323918)
54. Overcoming drug resistance in pancreatic cancer. Long J, Zhang Y, Yu X, Yang J, LeBrun DG, Chen C, Yao Q, Li M, Expert Opin Ther Targets 2011 15 817 828 10.1517/14728222.2011.566216 21391891
55. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo. Wang Y-W, Wang S-J, Zhou Y-N, Pan S-H, Sun B, J Cancer Res Clin Oncol 2012 138 785 797 10.1007/s00432-012-1152-z 22270965
56. Effects of beta-Aescin on the expression of nuclear factor-kappaB and tumor necrosis factor-alpha after traumatic brain injury in rats. Xiao G, Wei J, J Zhejiang Univ Sci B 2005 6 28 32 15593388
57. Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathway. Harikumar KB, Sung B, Pandey MK, Guha S, Krishnan S, Aggarwal BB, Mol Pharmacol 2010 77 818 827 10.1124/mol.109.062760 20103608
58. Beta-escin inhibits colonic aberrant crypt foci formation in rats and regulates the cell cycle growth by inducing p21(waf1/cip1) in colon cancer cells. Patlolla JMR, Raju J, Swamy MV, Rao CV, Mol Cancer Ther 2006 5 1459 1466 10.1158/1535-7163.MCT-05-0495 16818504 (Pubitemid 44070482)
59. Identification of beta-escin as a novel inhibitor of signal transducer and activator of transcription 3/Janus-activated kinase 2 signaling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. Tan SM, Li F, Rajendran P, Kumar AP, Hui KM, Sethi G, J Pharmacol Exp Ther 2010 334 285 293 10.1124/jpet.110.165498 20378717
60. β-Escin sodium inhibits inducible nitric oxide synthase expression via downregulation of the JAK/STAT pathway in A549 cells. Ji DB, Xu B, Liu JT, Ran FX, Cui JR, Mol Carcinog 2011 50 945 960 10.1002/mc.20762 21400616
61. Apoptosis of human cholangiocarcinoma cell lines induced by β-escin through mitochondrial caspase-dependent pathway. Shen D-Y, Kang J-H, Song W, Zhang W-Q, Li W-G, Zhao Y, Chen Q-X, Phytother Res 2011 25 1519 1526 10.1002/ptr.3435 21394804
62. Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O'Flaherty JD, Fennell DA, Richard D, O'Leary JJ, O'Byrne KJ, PLoS One 2013 8 54193 10.1371/journal.pone.0054193 23349823
63. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH, Cancer Res 2005 65 6934 6942 10.1158/0008-5472.CAN-04-4604 16061678 (Pubitemid 41060733)
64. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK, Reprod Biol Endocrinol 2003 1 66 10.1186/1477-7827-1-66 14609433 (Pubitemid 39130459)
65. Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, Kawagoe J, Takahashi K, Yada-Hashimoto N, Seino-Noda H, Sakata M, Motoyama T, Kurachi H, Testa JR, Tasaka K, Murata Y, Clin Cancer Res 2004 10 7645 7654 10.1158/1078-0432.CCR-04-0958 15569997 (Pubitemid 39557528)
66. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nakanishi C, Toi M, Nat Rev Cancer 2005 5 297 309 10.1038/nrc1588 15803156 (Pubitemid 40488635)
67. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Kim S-H, Juhnn Y-S, Song Y-S, Ann N Y Acad Sci 2007 1095 82 89 10.1196/annals.1397.012 17404021 (Pubitemid 47092440)
68. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, Price JE, Clin Cancer Res 2005 11 7490 7498 10.1158/1078-0432. CCR-05-1192 16243823 (Pubitemid 41507710)
69. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, D'Alessandro N, Cancer Lett 2005 224 53 65 10.1016/j.canlet.2004.10.051 15911101 (Pubitemid 40720367)
70. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Li M, Zhang Z, Hill DL, Wang H, Zhang R, Cancer Res 2007 67 1988 1996 10.1158/0008-5472.CAN-06-3066 17332326 (Pubitemid 46424215)
71. Dietary phenolic acids act as effective antioxidants in membrane models and in cultured cells, exhibiting proapoptotic effects in leukaemia cells. Zambonin L, Caliceti C, Vieceli Dalla Sega F, Fiorentini D, Hrelia S, Landi L, Prata C, Oxid Med Cell Longev 2012 2012 839298 22792417
72. Cinnamic acid induces apoptotic cell death and cytoskeleton disruption in human melanoma cells. Niero ELDO, Machado-Santelli GM, J Exp Clin Cancer Res 2013 32 31 10.1186/1756-9966-32-31 23701745
73. Induction of apoptosis by a potent caffeic acid derivative, caffeic acid undecyl ester, is mediated by mitochondrial damage in NALM-6 human B cell leukemia cells. Tomizawa A, Kanno S, Osanai Y, Goto A, Sato C, Yomogida S, Ishikawa M, Oncol Rep 2013 29 425 429 23229564
74. Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway. Yang Y-I, Lee K-T, Park H-J, Kim TJ, Choi YS, Shih I-M, Choi J-H, Carcinogenesis 2012 33 2488 2498 10.1093/carcin/bgs302 23027625
75. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. Arafa E-SA, Zhu Q, Barakat BM, Wani G, Zhao Q, El-Mahdy MA, Wani AA, Cancer Res 2009 69 8910 8917 10.1158/0008-5472.CAN-09-1543 19903849
76. Cellular survival: a play in three Akts. Datta S, Brunet A, Greenberg M, Genes Dev 1999 13 2905 2927 10.1101/gad.13.22.2905 10579998
77. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, Coppola D, Nicosia SV, Cheng JQ, Oncogene 2000 19 2324 2330 10.1038/sj.onc.1203598 10822383 (Pubitemid 30307208)
78. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV, Cheng JQ, Am J Pathol 2001 159 431 437 10.1016/S0002-9440(10)61714-2 11485901 (Pubitemid 32751073)
79. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV, Cheng JQ, Cancer Res 2001 61 5985 5991 11507039 (Pubitemid 32762525)
80. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, Michel K, Peifer M, Mermel C, Girard L, Peyton M, Gazdar AF, Minna JD, Garraway LA, Kashkar H, Pao W, Meyerson M, Thomas RK, Cancer Res 2009 69 3256 3261 10.1158/0008-5472.CAN-08- 4055 19351834
81. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ, Mol Cancer Ther 2010 9 1489 1502 10.1158/1535-7163.MCT-09-1171 20501798
82. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. Chen K-F, Chen H-L, Tai W-T, Feng W-C, Hsu C-H, Chen P-J, Cheng A-L, J Pharmacol Exp Ther 2011 337 155 161 10.1124/jpet.110.175786 21205925
83. RUNX3-mediated transcriptional inhibition of Akt suppresses tumorigenesis of human gastric cancer cells. Lin F-C, Liu Y-P, Lai C-H, Shan Y-S, Cheng H-C, Hsu P-I, Lee C-H, Lee Y-C, Wang H-Y, Wang C-H, Cheng JQ, Hsiao M, Lu P-J, Oncogene 2012 31 4302 4316 10.1038/onc.2011.596 22231444
84. Epigenetic downregulation of RUNX3 by DNA methylation induces docetaxel chemoresistance in human lung adenocarcinoma cells by activation of the AKT pathway. Zheng Y, Wang R, Song H-Z, Pan B-Z, Zhang Y-W, Chen L-B, Int J Biochem Cell Biol 2013 45 1 10 10.1016/j.biocel.2012.10.008 23098769
85. Apoptosis induced by benzyl isothiocyanate in gefitinib-resistant lung cancer cells is associated with Akt/MAPK pathways and generation of reactive oxygen species. Liu B-N, Yan H-Q, Wu X, Pan Z-H, Zhu Y, Meng Z-W, Zhou Q-H, Xu K, Cell Biochem Biophys 2013 66 81 92 10.1007/s12013-012-9456-9 23111983
86. Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway. Gao A-M, Ke Z-P, Wang J-N, Yang J-Y, Chen S-Y, Chen H, Carcinogenesis 2013 34 1806 1814 10.1093/carcin/bgt108 23563091
87. Disruption of epithelial cell-matrix interactions induces apoptosis. Frisch SM, Francis H, J Cell Biol 1994 124 619 626 10.1083/jcb.124.4.619 8106557 (Pubitemid 24064472)
88. Anchorage and growth regulation in normal and virus-transformed cells. Stoker M, O'Neill C, Berryman S, Waxman V, Int J Cancer 1968 3 683 693 10.1002/ijc.2910030517 5749478
89. Anoikis: cancer and the homeless cell. Liotta LA, Kohn E, Nature 2004 430 973 974 10.1038/430973a 15329701 (Pubitemid 39128370)
90. Anoikis mechanisms. Frisch SM, Screaton RA, Curr Opin Cell Biol 2001 13 555 562 10.1016/S0955-0674(00)00251-9 11544023 (Pubitemid 32817013)
91. Human MCF10A mammary epithelial cells undergo apoptosis following actin depolymerization that is independent of attachment and rescued by Bcl-2. Martin SS, Leder P, Mol Cell Biol 2001 21 6529 6536 10.1128/MCB.21.19.6529-6536.2001 11533241 (Pubitemid 32927420)
92. A novel form of constitutively active farnesylated Akt1 prevents mammary epithelial cells from anoikis and suppresses chemotherapy-induced apoptosis. Schmidt M, Hövelmann S, Beckers TL, Ho S, Br J Cancer 2002 87 924 932 10.1038/sj.bjc.6600566 12373610 (Pubitemid 35252971)
93. A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells. Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW, Whang EE, Cancer Res 2004 64 3987 3993 10.1158/0008-5472.CAN-04-0424 15173012 (Pubitemid 38697314)
94. Acquisition of anoikis resistance in human osteosarcoma cells does not alter sensitivity to chemotherapeutic agents. Díaz-Montero CM, McIntyre BW, BMC Cancer 2005 5 39 10.1186/1471-2407-5-39 15829011 (Pubitemid 41461090)
95. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, Post MD, Lu X, Broaddus RR, Spillman MA, Richer JK, Mol Cancer Ther 2012 11 2556 2565 10.1158/1535-7163.MCT-12-0463 23074172
96. The heat-shock proteins. Lindquist S, Craig EA, Annu Rev Genet 1988 22 631 677 10.1146/annurev.ge.22.120188.003215 2853609 (Pubitemid 19156675)
97. Folding of nascent polypeptide chains in a high molecular mass assembly with molecular chaperones. Frydman J, Nimmesgern E, Ohtsuka K, Hartl FU, Nature 1994 370 111 117 10.1038/370111a0 8022479 (Pubitemid 24229115)
98. HSP40 binding is the first step in the HSP90 chaperoning pathway for the progesterone receptor. Hernández MP, Chadli A, Toft DO, J Biol Chem 2002 277 11873 11881 10.1074/jbc.M111445200 11809754 (Pubitemid 34952744)
99. Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC). Jeong C-H, Park HB, Jang WJ, Jung SH, Seo YH, Bioorg Med Chem Lett 2014 24 224 227 10.1016/j.bmcl.2013.11.034 24345447
100. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez J-P, Shaw AT, Doebele RC, He S, Bates RC, Camidge DR, Morris SW, El-Hariry I, Proia DA, Cancer Discov 2013 3 430 443 10.1158/2159-8290.CD-12-0440 23533265
101. Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer. Ono N, Yamazaki T, Tsukaguchi T, Fujii T, Sakata K, Suda A, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y, Cancer Sci 2013 104 1346 1352 10.1111/cas.12237 23863134
102. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2. Gallerne C, Prola A, Lemaire C, Biochim Biophys Acta 1833 2013 1356 1366
103. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, Tailor P, Morimoto RI, Cohen GM, Green DR, Nat Cell Biol 2000 2 469 475 10.1038/35019501 10934466
104. Negative regulation of the Apaf-1 apoptosome by Hsp70. Saleh A, Srinivasula SM, Balkir L, Robbins PD, Alnemri ES, Nat Cell Biol 2000 2 476 483 10.1038/35019510 10934467
105. Phase I and pharmacologic study of 17-(allylamino)-17- demethoxygeldanamycin in adult patients with solid tumors. Grem JL, Morrison G, Guo X-D, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM, Neckers L, Wilson RH, J Clin Oncol 2005 23 1885 1893 10.1200/JCO.2005.12.085 15774780 (Pubitemid 46211366)
106. 3′Sulfogalactolipid binding specifically inhibits Hsp70 ATPase activity in vitro. Whetstone H, Lingwood C, Biochemistry 2003 42 1611 1617 10.1021/bi026735t 12578374 (Pubitemid 36205968)
107. Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy. Rérole A-L, Gobbo J, De Thonel A, Schmitt E, Pais de Barros JP, Hammann A, Lanneau D, Fourmaux E, Deminov O, Micheau O, Lagrost L, Colas P, Kroemer G, Garrido C, Cancer Res 2011 71 484 495 10.1158/0008-5472.CAN-10-1443 21224349
108. Ibuprofen enhances the anticancer activity of cisplatin in lung cancer cells by inhibiting the heat shock protein 70. Endo H, Yano M, Okumura Y, Kido H, Cell Death Dis 2014 5 1027 10.1038/cddis.2013.550 24481441
109. Human DNAJ in cancer and stem cells. Sterrenberg JN, Blatch GL, Edkins AL, Cancer Lett 2011 312 129 142 10.1016/j.canlet.2011.08.019 21925790
110. Heat shock protein 27 controls apoptosis by regulating Akt activation. Rane MJ, Pan Y, Singh S, Powell DW, Wu R, Cummins T, Chen Q, McLeish KR, Klein JB, J Biol Chem 2003 278 27828 27835 10.1074/jbc.M303417200 12740362 (Pubitemid 36899975)
111. HSP27 phosphorylation modulates TRAIL-induced activation of Src-Akt/ERK signaling through interaction with β-arrestin2. Qi S, Xin Y, Qi Z, Xu Y, Diao Y, Lan L, Luo L, Yin Z, Cell Signal 2014 26 594 602 10.1016/j.cellsig.2013. 11.033 24308965
112. Therapeutic strategies in epithelial ovarian cancer. Kim A, Ueda Y, Naka T, Enomoto T, J Exp Clin Cancer Res 2012 31 14 10.1186/1756-9966-31-14 22330607
113. Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27. Hsu H-S, Lin J-H, Huang W-C, Hsu T-W, Su K, Chiou S-H, Tsai Y-T, Hung S-C, Cancer 2011 117 1516 1528 10.1002/cncr.25599 21425153
114. Heat shock proteins 27, 40, and 70 as combinational and dual therapeutic cancer targets. McConnell JR, McAlpine SR, Bioorg Med Chem Lett 2013 23 1923 1928 10.1016/j.bmcl.2013.02.014 23453837
115. Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery. Prestwich GD, Acc Chem Res 2008 41 139 148 10.1021/ar7000827 17655274
116. Taking cell-matrix adhesions to the third dimension. Cukierman E, Pankov R, Stevens DR, Yamada KM, Science 2001 294 1708 1712 10.1126/science.1064829 11721053 (Pubitemid 33104840)
117. Culture of HepG2 liver cells on three dimensional polystyrene scaffolds enhances cell structure and function during toxicological challenge. Bokhari M, Carnachan RJ, Cameron NR, Przyborski SA, J Anat 2007 211 567 576 17711423 (Pubitemid 47456842)
118. Lumen formation by epithelial cell lines in response to collagen overlay: a morphogenetic model in culture. Hall HG, Farson DA, Bissell MJ, Proc Natl Acad Sci U S A 1982 79 4672 4676 10.1073/pnas.79.15.4672 6956885
119. Cell death and lumen formation in spheroids of MCF-7 cells. Do Amaral JB, Urabayashi MS, Machado-Santelli GM, Cell Biol Int 2010 34 267 274 10.1042/CBI20090024 19947922
120. MCF-7 cells as a three-dimensional model for the study of human breast cancer. Do Amaral JB, Rezende-Teixeira P, Freitas VM, Machado-Santelli GM, Tissue Eng Part C Methods 2011 17 1097 1107 10.1089/ten.tec.2011.0260 21882900
121. Three-dimensional tissue cultures: current trends and beyond. Page H, Flood P, Reynaud EG, Cell Tissue Res 2013 352 123 131 10.1007/s00441-012-1441-5 22729488
122. Gene expression in the third dimension: the ECM-nucleus connection. Spencer VA, Xu R, Bissell MJ, J Mammary Gland Biol Neoplasia 2010 15 65 71 10.1007/s10911-010-9163-3 20107877
123. Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines. Luca AC, Mersch S, Deenen R, Schmidt S, Messner I, Schäfer K-L, Baldus SE, Huckenbeck W, Piekorz RP, Knoefel WT, Krieg A, Stoecklein NH, PLoS One 2013 8 59689 10.1371/journal.pone. 0059689 23555746
124. Apoptosis, cell adhesion and the extracellular matrix in the three-dimensional growth of multicellular tumor spheroids. Santini MT, Rainaldi G, Indovina PL, Crit Rev Oncol Hematol 2000 36 75 87 10.1016/S1040-8428(00) 00078-0 11033298
125. Selective down-regulation of integrin receptors in spheroids of squamous cell carcinoma. Waleh NS, Gallo J, Grant TD, Murphy BJ, Kramer RH, Sutherland RM, Cancer Res 1994 54 838 843 8306347 (Pubitemid 24068346)
126. Integrin expression on colorectal tumor cells growing as monolayers, as multicellular tumor spheroids, or in nude mice. Hauptmann S, Denkert C, Löhrke H, Tietze L, Ott S, Klosterhalfen B, Mittermayer C, Int J Cancer 1995 61 819 825 10.1002/ijc.2910610613 7790117
127. A reliable tool to determine cell viability in complex 3-d culture: the acid phosphatase assay. Friedrich J, Eder W, Castaneda J, Doss M, Huber E, Ebner R, Kunz-Schughart LA, J Biomol Screen 2007 12 925 937 10.1177/1087057107306839 17942785 (Pubitemid 47548596)
128. Multicellular tumor spheroids: an underestimated tool is catching up again. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA, J Biotechnol 2010 148 3 15 10.1016/j.jbiotec.2010.01.012 20097238
129. In situ analysis of doxorubicin uptake and cytotoxicity in a 3D culture model of human HT-1080 fibrosarcoma cells. Fourré N, Millot J-M, Garnotel R, Jeannesson P, Anticancer Res 2006 26 4623 4626 17201187 (Pubitemid 46031540)
130. A multicellular 3D heterospheroid model of liver tumor and stromal cells in collagen gel for anti-cancer drug testing. Yip D, Cho CH, Biochem Biophys Res Commun 2013 433 327 332 10.1016/j.bbrc.2013.03.008 23501105
131. 3D collagen type I matrix inhibits the antimigratory effect of doxorubicin. Millerot-Serrurot E, Guilbert M, Fourré N, Witkowski W, Said G, Van Gulick L, Terryn C, Zahm J-M, Garnotel R, Jeannesson P, Cancer Cell Int 2010 10 26 10.1186/1475-2867-10-26 20707917
132. TM based 3D cell culture system as an in-vitro tumor model for anticancer studies. Godugu C, Patel AR, Desai U, Andey T, Sams A, Singh M, PLoS One 2013 8 53708 10.1371/journal.pone.0053708 23349734
133. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS, Blood 1999 93 1658 1667 10029595 (Pubitemid 29102494)
134. VLA-4-dependent myeloma cell adhesion. Sanz-Rodríguez F, Teixidó J, Leuk Lymphoma 2001 41 239 245 10.3109/10428190109057979 11378537 (Pubitemid 32499407)
135. Beta4 Integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Weaver VM, Lelièvre S, Lakins JN, Chrenek MA, Jones JCR, Giancotti F, Werb Z, Bissell MJ, Cancer Cell 2002 2 205 216 10.1016/S1535- 6108(02)00125-3 12242153 (Pubitemid 41043976)
136. ANTI-ADHESION evolves to a promising therapeutic concept in oncology. Schmidmaier R, Baumann P, Curr Med Chem 2008 15 978 990 10.2174/ 092986708784049667 18393855 (Pubitemid 351736400)
137. Adhesion-mediated apoptosis resistance in cancer. Westhoff M-A, Fulda S, Drug Resist Updat 2009 12 127 136 10.1016/j.drup.2009.08.001 19726220
138. 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing. Longati P, Jia X, Eimer J, Wagman A, Witt M-R, Rehnmark S, Verbeke C, Toftgård R, Löhr M, Heuchel RL, BMC Cancer 2013 13 95 10.1186/1471-2407-13-95 23446043
139. Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Loessner D, Stok KS, Lutolf MP, Hutmacher DW, Clements JA, Rizzi SC, Biomaterials 2010 31 8494 8506 10.1016/j.biomaterials.2010.07.064 20709389
140. Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment. Dong Y, Stephens C, Walpole C, Swedberg JE, Boyle GM, Parsons PG, McGuckin MA, Harris JM, Clements JA, PLoS One 2013 8 57056 10.1371/journal.pone.0057056 23451143
141. Evaluation of characteristics of CD44 + CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures. Chen J, Wang J, Chen D, Yang J, Yang C, Zhang Y, Zhang H, Dou J, BMC Cell Biol 2013 14 7 10.1186/1471-2121-14-7 23368632
142. Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. Yang T-M, Barbone D, Fennell DA, Broaddus VC, Am J Respir Cell Mol Biol 2009 41 14 23 10.1165/rcmb.2008-0320OC 19097992
143. Implication of necrosis-linked p53 aggregation in acquired apoptotic resistance to 5-FU in MCF-7 multicellular tumour spheroids. Lee SY, Jeong E, Jeon HM, Kim CH, Kang HS, Oncol Rep 2010 24 73 79 20514446
144. Activity of anticancer agents in a three-dimensional cell culture model. Nirmalanandhan VS, Duren A, Hendricks P, Vielhauer G, Sittampalam GS, Assay Drug Dev Technol 2010 8 581 590 10.1089/adt.2010.0276 20662735
145. Tumour-initiating cells vs. cancer "stem" cells and CD133: what's in the name? Neuzil J, Stantic M, Zobalova R, Chladova J, Wang X, Prochazka L, Dong L, Andera L, Ralph SJ, Biochem Biophys Res Commun 2007 355 855 859 10.1016/j.bbrc.2007.01.159 17307142 (Pubitemid 46366906)
146. Tumour stem cells and drug resistance. Dean M, Fojo T, Bates S, Nat Rev Cancer 2005 5 275 284 10.1038/nrc1590 15803154 (Pubitemid 40488633)
147. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Visvader JE, Lindeman GJ, Nat Rev Cancer 2008 8 755 768 10.1038/nrc2499 18784658
148. Identification of gastric cancer stem cells using the cell surface marker CD44. Takaishi S, Okumura T, Tu S, Wang SSW, Shibata W, Vigneshwaran R, Gordon SAK, Shimada Y, Wang TC, Stem Cells 2009 27 1006 1020 10.1002/stem.30 19415765
149. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, Rocco G, Pirozzi G, Eur J Cardiothorac Surg 2009 36 446 453 10.1016/j.ejcts.2009.03.063 19464919
150. High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. Awad O, Yustein JT, Shah P, Gul N, Katuri V, Neill AO, Kong Y, Brown ML, Toretsky JA, Loeb DM, O'Neill A, PLoS One 2010 5 13943 10.1371/journal.pone.0013943 21085683
151. The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Moserle L, Indraccolo S, Ghisi M, Frasson C, Fortunato E, Canevari S, Miotti S, Tosello V, Zamarchi R, Corradin A, Minuzzo S, Rossi E, Basso G, Amadori A, Cancer Res 2008 68 5658 5668 10.1158/0008-5472. CAN-07-6341 18632618
152. Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells. Rybak AP, He L, Kapoor A, Cutz J-C, Tang D, Biochim Biophys Acta 1813 2011 683 694
153. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Pastrana E, Silva-Vargas V, Doetsch F, Cell Stem Cell 2011 8 486 498 10.1016/j.stem.2011.04.007 21549325
154. CD44 in cancer progression: adhesion, migration and growth regulation. Marhaba R, Zöller M, J Mol Histol 2004 35 211 231 15339042 (Pubitemid 40585308)
155. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE, Proc Natl Acad Sci U S A 2007 104 973 978 10.1073/pnas.0610117104 17210912 (Pubitemid 46154721)
156. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Marchitti SA, Brocker C, Stagos D, Vasiliou V, Expert Opin Drug Metab Toxicol 2008 4 697 720 10.1517/17425255.4.6.697 18611112 (Pubitemid 352003194)
157. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Magni M, Shammah S, Schiró R, Mellado W, Dalla-Favera R, Gianni AM, Blood 1996 87 1097 1103 8562935 (Pubitemid 26043537)
158. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Sládek NE, Kollander R, Sreerama L, Kiang DT, Cancer Chemother Pharmacol 2002 49 309 321 10.1007/s00280-001-0412-4 11914911 (Pubitemid 34253270)
159. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Cheung AMS, Wan TSK, Leung JCK, Chan LYY, Huang H, Kwong YL, Liang R, Leung AYH, Leukemia 2007 21 1423 1430 10.1038/sj.leu.2404721 17476279 (Pubitemid 46965282)
160. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G, Cell Stem Cell 2007 1 555 567 10.1016/j.stem.2007.08.014 18371393 (Pubitemid 350056407)
161. Aldehyde dehydrogenase: Its role as a cancer stem cell marker comes down to the specific isoform. Marcato P, Dean CA, Giacomantonio CA, Lee PWK, Cell Cycle 2011 10 1378 1384 10.4161/cc.10.9.15486 21552008
162. Retinoic acid and cAMP inhibit rat hepatocellular carcinoma cell proliferation and enhance cell differentiation. Ionta M, Rosa MCC, Almeida RBB, Freitas VMM, Rezende-Teixeira P, Machado-Santelli GMM, Braz J Med Biol Res 2012 45 721 729 10.1590/S0100-879X2012007500087 22618858
163. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC, J Exp Med 1996 183 1797 1806 10.1084/jem.183.4.1797 8666936 (Pubitemid 26134320)
164. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, Laino L, De Francesco F, Papaccio G, FASEB J 2013 27 13 24 10.1096/fj.12-218222 23024375
165. Entrapped doxorubicin nanoparticles for the treatment of metastatic anoikis-resistant cancer cells. Lee H, Park S, Kim JB, Kim J, Kim H, Cancer Lett 2013 332 110 119 10.1016/j.canlet.2013.01.021 23348696
166. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Reynolds BA, Weiss S, Science 1992 255 1707 1710 10.1126/science.1553558 1553558
167. Cancer stem cells in lung cancer: evidence and controversies. Alamgeer M, Peacock CD, Matsui W, Ganju V, Watkins DN, Respirology 2013 18 757 764 10.1111/resp.12094 23586700 Nível Superior